T
he sequencing of the human genome offers substantial benefits to clinical medicine, including the ability to identify genes that influence the pathogenesis of common diseases. One approach to the identification of such genes is the evaluation of selected polymorphisms in genes that are implicated in a given disease, either because they encode proteins related to the disease process or because they are located within chromosomal regions identified in linkage studies.
Hypertension is a complex multifactorial and polygenic disorder that is thought to result from an interaction between an individual's genetic background and various environmental factors. 1 Given that hypertension is a major risk factor for coronary heart disease (CHD), stroke, and chronic renal failure, personalized prevention of hypertension is an important public health goal. One approach to personalized prevention and selection of the most appropriate treatment for hypertension is to identify disease susceptibility genes. Although genetic linkage analyses [2] [3] [4] [5] [6] and candidate gene association studies 2, [7] [8] [9] [10] have implicated various loci and genes in predisposition to hypertension, the genes that confer genetic susceptibility to this condition remain to be identified definitively.
We have now performed a large-scale association study of 150 candidate gene polymorphisms and hypertension in 4853 Japanese individuals. The purpose of the present study was to identify gene polymorphisms for reliable assessment of the genetic component of hypertension and thereby to contribute to the personalized prevention of this condition.
Methods

Study Population
The study population comprised 4853 unrelated Japanese individuals (2688 men, 2165 women) who either visited outpatient clinics or were admitted to one of the six participating hospitals (Gifu Prefectural Gifu, Tajimi, and Gero Hotspring Hospitals; Hirosaki University Hospital; Reimeikyo Rehabilitation Hospital; and Yokohama General Hospital) between October 2002 and March 2005. The 2818 subjects (1677 men, 1141 women) with hypertension either had a systolic blood pressure (BP) of Ն140 mm Hg or diastolic BP of Ն90 mm Hg (or both) or had taken antihypertensive drugs. Individuals with valvular heart disease, congenital malformations of the heart or vessels, or renal or endocrinologic diseases that cause secondary hypertension were excluded from the study. The control subjects comprised a total of 2035 individuals (1011 men, 1024 women) who visited the outpatient clinics of participating hospitals for an annual health checkup. They had normal BP (systolic BP of Ͻ140 mm Hg and diastolic BP of Ͻ90 mm Hg) and no history of hypertension or of taking antihypertensive medication. Individuals who had CHD or had taken either steroids or vasodilators such as calcium channel blockers and nitrates were excluded from the control group. However, individuals who had taken nonsteroidal anti-inflammatory drugs were not excluded from the control group. The control individuals either had or did not have diabetes mellitus, hypercholesterolemia, or obesity.
Blood pressure was measured at least twice with subjects having rested in the sitting position for Ͼ10 min; the measurements were taken by a skilled physician according to the guidelines of the American Heart Association. 11 The study protocol complied with the Declaration of Helsinki and was approved by the Committees on the Ethics of Human Research of Mie University School of Medicine, Hirosaki University School of Medicine, Gifu International Institute of Biotechnology, and participating hospitals, and written informed consent was obtained from each participant.
Selection of Polymorphisms
Our aim was to identify genes significantly associated with hypertension in the Japanese population in a case-control association study by examining the relation of one to three polymorphisms of each gene with hypertension. We selected 128 candidate genes that have been characterized and were suggested to be associated with hypertension on the basis of a comprehensive overview of vascular biology, platelet and leukocyte biology, coagulation and fibrinolysis cascades, neurologic factors, as well as lipid, glucose, and homocysteine metabolism and other metabolic factors. We further selected 150 polymorphisms of these genes, most of which are located in the promoter region, exons, or splice donor or acceptor sites of introns and might therefore be expected to result in changes in the function or expression of the encoded protein. Candidate genes were selected with the use of public databases including PubMed (NCBI), Online Mendelian Inheritance in Man (NCBI), and Hypertension Candidate Gene SNPs (Case Western Reserve University, http://cmbi.bjmu.edu. cn/genome/candidates/snps.html). Polymorphisms of candidate genes were selected from published studies and by searching PubMed. Wild-type and variant alleles were determined according to these sources. Given that data from the International HapMap Project were not used, the polymorphisms selected in the present study did not allow a comprehensive haplotype screen for each gene.
Genotyping of Polymorphisms
Venous blood (7 mL) was collected into tubes containing 50 mmol/L EDTA (disodium salt), and genomic DNA was isolated with a kit (Genomix; Talent, Trieste, Italy). Genotypes of the 150 polymorphisms were determined (G&G Science, Fukushima, Japan) by a method that combines the polymerase chain reaction and sequence-specific oligonucleotide probes with the use of suspension array technology (Luminex 100; Luminex, Austin, TX). Detailed methodology for genotyping was described previously.
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Statistical Analysis
Clinical data were compared between subjects with hypertension and controls by the unpaired Student t test. Qualitative data were compared by the 2 test. Allele frequencies were estimated by the gene counting method, and the 2 test was used to identify departures from Hardy-Weinberg equilibrium. The genotype distribution of each autosomal polymorphism was compared between subjects with hypertension and controls by the 2 test (3 by 2); for polymorphisms on the X chromosome, allele frequencies were compared by the 2 test (2 by 2). Polymorphisms related to hypertension were examined by multivariable logistic regression analysis with adjustment for covariates, with hypertension as a dependent variable and independent variables including age, sex (0 ϭ woman, 1 ϭ man), body mass index (BMI), smoking status (0 ϭ never a smoker, 1 ϭ former or current smoker), and genotype of each polymorphism. As to smoking status, adjustment was not made for never a smoker versus former smoker or for former smoker versus current smoker. Each genotype was assessed according to dominant, recessive, and two additive (additive 1 and 2) genetic models, and the P value, odds ratio, and 95% confidence interval were calculated. Each genetic model comprised two groups: the combined group of variant homozygotes and heterozygotes versus wild-type homozygotes for the dominant model; variant homozygotes versus the combined group of wild-type homozygotes and heterozygotes for the recessive model; heterozygotes versus wild-type homozygotes for the additive 1 model; and variant homozygotes versus wild-type homozygotes for the additive 2 model. For combined genotype analysis, multivariable logistic regression analysis was performed with hypertension as a dependent variable and independent variables including age, sex, BMI, smoking status, and combined genotypes. Each genotype was assessed according to a dominant or recessive model based on statistical significance, and each combined genotype was compared with that which conferred the highest genetic risk for hypertension. We also performed a stepwise forward selection procedure to examine the effects of genotypes as well as of other covariates on hypertension. The levels for inclusion in and exclusion from the model were 0.25 and 0.1, respectively. Given the multiple comparisons of genotypes with hypertension, we adopted a strict criterion of statistical significance to avoid type I error; a P value of Ͻ .01 was considered statistically significant for association. For other clinical background data, a P value of Ͻ .05 was considered statistically significant. Statistical significance was examined by twosided tests, and statistical analyses were performed with JMP version 5.1 software (SAS Institute, Cary, NC).
Results
The characteristics of the 4853 study subjects are shown in Table 1 . Age, the frequency of male subjects, BMI, and the prevalence of diabetes mellitus and hypercholesterolemia were greater in subjects with hypertension than in controls. On the basis of comparisons of genotype distributions or allele frequencies by the 2 test, 17 polymorphisms with P values of .0028 to .0576 (including five of borderline significance at a significance level of P Ͻ .05) were related to the prevalence of hypertension (data not shown). These polymorphisms were further analyzed for their potential association with hypertension.
Multivariable logistic regression analysis with adjustment for age, sex, BMI, and the prevalence of smoking revealed that the 1648G¡A polymorphism of the integrin, ␣-2, gene (ITGA2, dominant and additive 1 models), the Ϫ30G¡A polymorphism of the glucokinase gene (GCK, dominant model), the A¡G polymorphism of the hypertension-associated SA, rat, homolog of, gene (SAH, dominant model), and the 1117C¡A polymorphism of the prostaglandin I 2 synthase gene (PTGIS, dominant model) were significantly (P Ͻ .01) associated with the prevalence of hypertension ( Table 2 ). The 1648A allele of ITGA2, the Ϫ30A allele of GCK, the G allele of SAH, and the 1117A allele of PTGIS were protective against this condition. The dominant model for ITGA2 compared the combined group of the AA and AG genotypes (7.5% and 9.7% in hypertensive and control individuals, respectively) with individuals with the GG genotype (92.6% and 90.2% in hypertensive and control individuals, respectively). The genotype distributions for these four polymorphisms are shown in Table 3 and were in Hardy-Weinberg equilibrium in both controls and subjects with hypertension. Only one polymorphism of each of these four genes was genotyped in the present study.
We performed a stepwise forward selection procedure to examine the effect (contribution rate, R 2 ) of genotypes for the 1648G¡A polymorphism of ITGA2, the Ϫ30G¡A polymorphism of GCK, the A¡G polymorphism of SAH, and the 1117C¡A polymorphism of PTGIS as well as of age, sex, BMI, and smoking status on hypertension. Age (P Ͻ .0001, R 2 ϭ 0.0087), sex (P Ͻ .0001, R 2 ϭ 0.0075), BMI (P Ͻ .0001, R 2 ϭ 0.0059), ITGA2 genotype (dominant model; P ϭ .0022, R 2 ϭ 0.0014), GCK genotype (dominant model; P ϭ .0048, R 2 ϭ 0.0012), and PTGIS genotype (dominant model; P ϭ .0082, R 2 ϭ 0.0011), in descending order of statistical significance (P Ͻ .01), were found to affect the prevalence of hypertension independently.
Finally, we calculated the odds ratio, 95% confidence interval, and P value for combined genotypes in assessment of the genetic component of hypertension. Combined genotype analysis of three polymorphisms (1648G¡ A of ITGA2, Ϫ30G¡A of GCK, and 1117C¡A of PTGIS) revealed that the lowest odds ratio of 0.47 was obtained with the combined genotype of AA or AG for ITGA2, GA or AA for GCK, and CC for PTGIS compared with the combined genotype of GG for ITGA2, GG for GCK, and CC for PTGIS (Table 4) .
Discussion
We examined the relations of 150 polymorphisms in 128 candidate genes to hypertension. Our large-scale association study with 4853 subjects revealed that the 1648G¡A polymorphism of ITGA2, the Ϫ30G¡A polymorphism of GCK, and the 1117C¡A polymorphism of PTGIS were significantly associated with the prevalence of hypertension in a Japanese population. Combined genotype analysis revealed that the combined genotype of AA or AG for ITGA2, GA or AA for GCK, and CC for PTGIS, with a frequency of 1.1% and 2.0% in hypertensive and control individuals, respectively, was protective (odds ratio, 0.47) against hypertension. The most common combined genotype of GG for ITGA2, GG for GCK, and CC for PTGIS thus increased the risk for this condition. The integrin ␣2 chain (ITGA2, platelet glycoprotein Ia) is a component of the major receptor for collagen (␣2␤1 integrin). 13 Deficiency of ITGA2 can result in hemorrhagic diathesis, 14 whereas a high ␣2␤1 integrin density has been shown to be related to an increased attachment of platelets to type I collagen under conditions of high shear. 15 The 1648G¡A (Glu505Lys) polymorphism of ITGA2 is responsible for the immunogenic Br b/a (HPA5b/a) polymorphism. 16 Given that the Glu505Lys polymorphism is located in the cation-binding domain of ITGA2, it may influence the interaction of ␣2␤1 integrin with its ligands. The 1648G¡A (Glu505Lys) polymorphism of ITGA2 was shown to be associated with CHD in low-risk individuals, with the GG genotype being overrepresented in patients with CHD. 17 We have now shown that this polymorphism of ITGA2 was associated with hypertension, with the A allele representing a protective factor for this condition. This is the first demonstration of an association of the 1648G¡A (Glu505Lys) polymorphism of ITGA2 with hypertension, although the underlying molecular mechanism remains to be elucidated. Activation of platelet function in individuals with hypertension has been recognized. 18 Activated platelets release platelet microparticles, the circulating concentration of which is increased in individuals with severe hypertension and is positively related to systolic and diastolic BP. 19 The effects of the 1648G¡A (Glu505Lys) polymorphism of ITGA2 on platelet function may thus account for its association with hypertension.
Glucokinase is expressed in pancreatic ␤ cells and hepatocytes, with its expression being controlled by two tissue-specific gene promoters. 20 Pancreatic glucokinase serves as the sensor for glucose, which regulates insulin secretion. 21 Mutations of GCK account for 10% to 50% of cases of maturity-onset diabetes of the young. 21 The Table 3 . Genotype distributions of polymorphisms significantly (P Reason for selection: * Polymorphism is located in an exon with an amino acid substitution; † polymorphism is located in the promoter; ‡ polymorphism is located in an intron but was shown to be related to hypertension 30 ; § polymorphism is located in an exon without an amino acid substitution but was suggested to be related to hypertension.
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Ϫ30G¡A polymorphism of GCK, which is located in the ␤ cell-specific promoter, was shown to be associated with reduced ␤ cell function and impaired glucose tolerance in Japanese. 22, 23 The A allele of this polymorphism was also shown to increase the risk for CHD and was consistently related to this condition after adjustment for type 2 diabetes mellitus in a white population. 24 The risk for CHD conferred by the A allele was even greater in individuals with type 2 diabetes mellitus than in nondiabetic individuals. We have now shown that the Ϫ30G¡A polymorphism of GCK was associated with hypertension, with the A allele being protective against this condition. Although GCK is a candidate gene for diabetes mellitus, the Ϫ30G¡A polymorphism of GCK was not associated with type 2 diabetes in the present study (data not shown). The mechanisms responsible for the association of the A variant with an increased risk of CHD, 24 with reduced ␤ cell function and impaired glucose tolerance, 22, 23 and with a reduced risk of hypertension (present study) remain to be elucidated. It is possible that the Ϫ30G¡A polymorphism of GCK is in linkage disequilibrium with other polymorphisms of nearby genes that are actually responsible for the protective effect against hypertension. A polymorphism (Ϫ258G¡A) located in the liver-specific promoter of GCK was also shown to be associated with hypertension in a Taiwanese population. 25 Prostaglandin I 2 (prostacyclin) is a powerful vasodilator, inhibits the growth of vascular smooth muscle cells, and is the most potent endogenous inhibitor of platelet aggregation. 26, 27 Variations of PTGIS that modulate prostacyclin synthesis might therefore be expected to play an important role in the pathophysiology of cardiovascular disease. Iwai et al 28 identified a repeat polymorphism in the promoter region of PTGIS that was associated with promoter activity. These researchers showed that the genotype associated with lower transcriptional activity was also associated with higher pulse pressure in the overall population (and especially in women) as well as with a higher systolic BP in relatively older participants in a population-based study. The 1117C¡A polymorphism in exon 8 of PTGIS was shown to be associated with the prevalence of myocardial infarction, with the CC genotype representing a risk factor for this condition. 29 The CC genotype was also related to high systolic BP, although the statistical significance of this association was borderline. We have now shown that the 1117C¡A polymorphism of PTGIS was significantly associated with hypertension, with the C allele representing a risk factor for this condition. Given that the 1117C¡A polymorphism does not cause an amino acid change (Arg373Arg), it would not be expected to have a direct effect on the expression of PTGIS or the function of prostaglandin I 2 synthase. 29 This polymorphism may therefore be a genetic marker that is in linkage disequilibrium with other polymorphisms in PTGIS or nearby genes that confer susceptibility to hypertension.
Given the multiple comparisons of genotypes with hypertension in the present study, we adopted a strict criterion (P Ͻ .01) for statistical significance of association. It is not possible, however, to exclude completely potential statistical errors such as false positives. It is also possible that one or more of the polymorphisms associated with hypertension in our study are in linkage disequilibrium with polymorphisms of other nearby genes that are actually responsible for the development of this condition. Furthermore, the relevance of the identified polymorphisms to gene transcription or to protein structure or function was not determined in the present study. Our results suggest that the frequencies of the common alleles of three polymorphisms of ITGA2, GCK, and PTGIS are increased in hypertensive individuals, and that the protective effect of these polymorphisms is conferred by rare genotypes. However, determination of combined genotypes for these polymorphisms may prove informative for assessment of the genetic component of hypertension.
Given that multiple variants, each having a small effect, will ultimately be found to be responsible for a large fraction of the genetic component of essential hypertension, further identification of hypertension susceptibility genes will allow more accurate assessment of the genetic component of this condition.
